OREANDA-NEWS. May 06, 2009. The Expert Council on Developing Competition in the Social Sphere and Health Care, at the Federal Antimonopoly Service (FAS Russia), discussed and approved in general the "Strategy for Developing the Pharmaceutical Industry of the Russian Federation for the Period through to 2020", formulated by the Ministry of Industry and Commerce of the Russian Federation, reported the press-centre of FAS Russia.

Members of the Expert Council emphasized the positive value of the Strategy for determining the directions of systemic and intergrated development of the pharmaceutic industry in the Russian Federation.

At the same time, the Expert Council believes that the Strategy must be harmonized with the draft Federal Law "On Introducing Amendments to the Federal Law "On Medications" and the "Concept of Developing the Health Care System in the Russian Federation for the Period through to 2020".

Reference:
The primary objective of Strategy for developing the national pharmaceutical industry for the period through to 2020 is to create conditions for the industry transition to innovative developmental model, which shall lead to better provision of the population, health care institutions and the armed forces of the Russian Federation with the Russian-made medications, generally raising provision of medications to the needy to the average level of medication provision in Europe (in terms of both quantity and quality of drugs).

The main aims of the Strategy:

- Improving provision of the population, health care institutions and the armed forces of the Russian Federation with the Russian-made, vital and the most important medications, and medications for treatment of rare diseases

- Enhancing competitive ability of the Russian pharmaceutical industry by harmonizing the national standards for medication development and production with the international requirements

- Stimulating development and production of innovative medications

- Protecting domestic market from unfair competition and levelling the market access conditions for Russian and domestic producers

- Technological re-equipment of the Russian pharmaceutical industry.